Sylvester Comprehensive Cancer Center shared a post on LinkedIn:
“Juan Pablo Alderuccio, M.D., an associate professor of clinical medicine in the Division of Hematology at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, has been named a recipient of the American Society of Hematology (ASH) Scholar Award, a competitive national honor that supports early-career physician-scientists pursuing innovative research in blood cancers.
ASH is awarded its 2026 Scholar Awardto 53 early-career investigators dedicated to careers in hematology research.
The ASH Scholar Award recognizes hematologists whose work shows strong promise for advancing patient care through original research. For Dr. Alderuccio, the award underscores his growing influence in the field of lymphoma research and his commitment to improving outcomes for patients with some of the most challenging forms of the disease.
Specialty
Dr. Alderuccio specializes in the study and treatment of lymphoma, with a particular focus on difficult-to-treat B-cell lymphomas. These cancers often resist standard therapies or recur after initial treatment, leaving patients with limited options. His research aims to address that gap by designing and leading clinical trials that test novel treatment combinations intended to maximize effectiveness while minimizing toxicity.
‘At the heart of my work is the goal of developing therapies that not only work better but are also more tolerable for patients,’ Dr. Alderuccio said. ‘Many individuals with relapsed or refractory lymphoma have already undergone intensive treatment. It’s critical that new approaches improve survival without significantly diminishing quality of life.’
His research centers on combining agents that have demonstrated strong antitumor activity with favorable safety profiles. By thoughtfully pairing these therapies, Dr. Alderuccio seeks to enhance their overall impact while reducing the cumulative side effects that can limit a patient’s ability to continue treatment. This approach reflects a broader shift in oncology toward more precise, patient-centered care.
Sylvester Role
At Sylvester, Dr. Alderuccio plays a dual role as both a clinician and an investigator. He cares for patients with lymphoma while also leading research efforts that translate laboratory and early clinical findings into real-world therapies. This close connection between research and patient care allows him to identify unmet needs at the bedside and address them through carefully designed clinical trials.
Colleagues describe Dr. Alderuccio as a physician-scientist who bridges innovation and compassion. His work is closely aligned with Sylvester’s mission to advance cancer care through cutting-edge research and multidisciplinary collaboration. By working alongside laboratory scientists, biostatisticians and fellow clinicians, he helps ensure that new therapies are rigorously tested and rapidly integrated into clinical practice when proven effective.
Critical Support
The ASH Scholar Award provides critical support for this type of research by offering protected time and funding that allow recipients to focus on building independent research programs. For Dr. Alderuccio, the award will help expand his ongoing clinical trials and support the development of new studies aimed at patients with limited treatment options.
Beyond his research contributions, Dr. Alderuccio is also dedicated to education and mentorship. As an associate professor, he trains medical students, residents and fellows, emphasizing evidence-based care and the importance of clinical research in advancing medicine. He encourages trainees to view clinical trials not as a last resort, but as a vital component of high-quality cancer care.
As lymphoma treatment continues to evolve, Dr. Alderuccio’s work reflects a broader effort to move beyond one-size-fits-all therapies. Through innovative trial design and a focus on balancing efficacy with safety, he is helping shape the next generation of treatments for B-cell lymphomas.
‘Recognitions like the ASH Scholar Award underscore the importance of innovative, patient-centered research,’ Dr. Alderuccio said. ‘Our goal is to bring forward safer, more effective options for people facing the toughest forms of lymphoma, and this support helps us move those treatments from concept to clinic’.”
More posts featuring ASH on OncoDaily.